Helicos BioSciences, a developer of genetic analysis technologies for the research, drug discovery and clinical diagnostics markets, announced the terms of its IPO Monday. The company plans to offer 5.4 million shares at a price between $13.00 and $15.00. UBS is the bookrunner on the deal.
